About Foundation Medicine
                            Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.                        
                                                    
                                    Headquarters
                                    Foundation Medicine, Cambridge
                                
                                                                                                
                                    Founded
                                    2010-01-01
                                
                                                                
                                                                
                                    Industry
                                    Biotechnology, Genetics, Health Care, Medical
                                
                                                                                                
                                    Last Funding Type
                                    Series B
                                
                                                                                                    
                                        Valuation
                                        0.5
                                    
                                                                                                
                                                                        Total Funding
                                    $96.50 million dollars
                                
                                                                                                
                                    IPO Status
                                    Public
                                
                                                            Financial
                                Foundation Medicine is advancing personalized cancer therapies through methods for predicting treatment response to mono-immunotherapy and determining tumor mutational burden (TMB) using sequence read data. They are also developing systems for identifying HLA variants and methods for multigene analysis of tumor samples. Their research includes detecting BRAF gene fusions and using tumor heterogeneity scores as prognostic biomarkers. These efforts focus on enhancing diagnostic precision and tailoring cancer treatments.
                            
                            
                                    Funding Rounds
                                    4
                                
                                                                                                
                                    Number of Lead Investors
                                    1
                                
                                                                                                
                                                                        Total Funding Amount 
                                    $96.50 million dollars
                                
                                                                                                
                                    Number of Investors
                                    9